Rare Nephrology News
Disease Profile
B-cell lymphoma
Prevalence estimates on Rare Medical Network websites are calculated based on data available from numerous sources, including US and European government statistics, the NIH, Orphanet, and published epidemiologic studies. Rare disease population data is recognized to be highly variable, and based on a wide variety of source data and methodologies, so the prevalence data on this site should be assumed to be estimated and cannot be considered to be absolutely correct.
#N/A
Age of onset
#N/A
ICD-10
#N/A
Inheritance
Autosomal dominant A pathogenic variant in only one gene copy in each cell is sufficient to cause an autosomal dominant disease.
Autosomal recessive Pathogenic variants in both copies of each gene of the chromosome are needed to cause an autosomal recessive disease and observe the mutant phenotype.
X-linked
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
dominant X-linked dominant inheritance, sometimes referred to as X-linked dominance, is a mode of genetic inheritance by which a dominant gene is carried on the X chromosome.
X-linked
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
recessive Pathogenic variants in both copies of a gene on the X chromosome cause an X-linked recessive disorder.
Mitochondrial or multigenic Mitochondrial genetic disorders can be caused by changes (mutations) in either the mitochondrial DNA or nuclear DNA that lead to dysfunction of the mitochondria and inadequate production of energy.
Multigenic or multifactor Inheritance involving many factors, of which at least one is genetic but none is of overwhelming importance, as in the causation of a disease by multiple genetic and environmental factors.
Not applicable
Other names (AKA)
Lymphoma, B-Cell
Categories
Rare Cancers
Summary
B
Treatment
FDA-Approved Treatments
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products.
- Tositumomab and iodine I 131 tositumomab(Brand name: Bexxar®) Manufactured by GlaxoSmithKline
FDA-approved indication: Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and withouttransformation , whose disease is refractory to Rituximab and has relapsed followingchemotherapy
National Library of Medicine Drug Information Portal
Medline Plus Health Information - Pembrolizumab(Brand name: Keytruda) Manufactured by Merck, Sharp & Dohme Corp.
FDA-approved indication: June 2018 approved for the treatment of adult and pediatric patients with refractory primary mediastinal large Bcell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy.
National Library of Medicine Drug Information Portal
Medline Plus Health Information - Tisagenlecleucel-T(Brand name: Kymriah) Manufactured by Novartis Pharmaceuticals Corporation
FDA-approved indication: May 2018, KYMRIAH is a CD19-directed genetically modified autologous T-cellimmunotherapy indicated for the treatment of patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma who received two or more lines of systemic therapy.
National Library of Medicine Drug Information Portal
Medline Plus Health Information - Rituximab(Brand name: Rituxan® (injection)) Manufactured by Genentech, Inc.
FDA-approved indication: Treatment of non-Hodgkin's B-cell lymphoma.
National Library of Medicine Drug Information Portal
Medline Plus Health Information - Venetoclax(Brand name: Venclexta) Manufactured by AbbVie Inc.
FDA-approved indication: June 2018, venetoclax (Venclexta) received expanded approval for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17pdeletion , who have received at least one prior therapy.
National Library of Medicine Drug Information Portal
Medline Plus Health Information - Ibritumomab tiuxetan(Brand name: Zevalin) Manufactured by Cell Therapeutics, Inc.
FDA-approved indication: Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin's lymphoma.
National Library of Medicine Drug Information Portal
Medline Plus Health Information - idelalisib(Brand name: Zydelig) Manufactured by Gilead Sciences, Inc
FDA-approved indication: (1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies; and (3) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.
National Library of Medicine Drug Information Portal
Organizations
Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.
Organizations Supporting this Disease
-
Leukemia and Lymphoma Society
3 International Drive, Suite 200
Rye Brook, NY 10573
Toll-free: 1-(800) 955-4572 (patients and families)
Telephone: 1-(888) 557-7177 (general)
E-mail: https://www.lls.org/content/contact-us
Website: https://www.lls.org/
Learn more
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
Where to Start
- The American Cancer Society provides information on B-cell lymphoma. Please click on the link to access this resource.
- Mayo Clinic has an information page on B-cell lymphoma.
- MedlinePlus was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.
- The National Cancer Institute provides the most current information on cancer for patients, health professionals, and the general public.
In-Depth Information
- Medscape Reference provides information on this topic. You may need to register to view the medical textbook, but registration is free.
- The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
- PubMed is a searchable database of medical literature and lists journal articles that discuss B-cell lymphoma. Click on the link to view a sample search on this topic.
References
- Ajeet Gajra, MD. B-Cell Lymphoma. MedlinePlus. September 2015; https://emedicine.medscape.com/article/202677-overview.
- Adult Non-Hodgkin Lymphoma Treatment (PDQ®). National Cancer Institute. November 2015; https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq#section/_129.
- Non-Hodgkin's lymphoma. Mayo Clinic. January 2015; https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/basics/definition/con-20027792.